Launch targets $16 billion SGLT-2 inhibitor market that serves 33 million type II diabetics in the US, many of whom are uninsured and underinsured and whose out-of-pocket costs exceed Brenzavvy's cash price
Proprietary EinsteinRx™ artificial intelligence pharmacy platform empowers the 6,500+ pharmacies in the Wellgistics Pharmacy Network to educate patients and providers on the advantages of Brenzavvy vs. Jardiance® and other SGLT-2 inhibitors
Reduced out-of-pocket costs for patients, paired with a patient-education revenue opportunity for pharmacists, are designed to support broader market access to Brenzavvy and enhance the overall care experience
Launch establishes a new model for next-generation reformulated drugs that offer patient-specific product advantages compared with entrenched market leaders
The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have access to controlled substances for legitimate medical use.
Today, the evidence shows the opposite: DEA officials laundering cartel money, DEA lawyers defending unconstitutional judicial processes, DEA executives cycling into industry roles they once regulated and DEA policies obstructing legitimate FDA authorized medical research.
Read More
"Queer Safety: Building Truly Affirming Systems for LGBTQ+ and Neurodivergent Lives"
A Candid Conversation on Safety, Ethics, and Affirming Care for LGBTQ+ and Neurodivergent Communities
Read More
MMJ International Holdings Exposes the Impossible Federal Catch-22 Blocking FDA Regulated Cannabis Medicine. "This is an equation with no solution. To follow the rule is to commit a felony, and to follow the law is to violate the rule. This is the first paradox I've encountered that violates logic and the U.S. criminal code simultaneously." stated Duane Boise, CEO MMJ International Holdings.
Read More
"President Trump is facing an impossible landscape created by years of regulatory neglect. We built a federally compliant, pharmaceutical grade marijuana medicine to bring order to that chaos. MMJ offers the President a path that respects the law, protects patients, and restores integrity to cannabinoid science."
-Duane Boise, President & CEO, MMJ International Holdings
Jaguar's requesting advice from EMA on EU approval pathway for general diarrhea of FDA conditionally approved Canalevia®
A novel non-antibiotic approach to diarrhea treatment is important because there are no FDA-approved drugs to treat general diarrhea in dogs, the second most common reason for visits to veterinary emergency hospitals
Read More
- New Composition of Matter Intellectual Property ("IP") Filing Centered on First-in-Class, Fully Synthetically Manufactured Halneuron®-
- New Synthetic Process to be Used for Phase 3 Development Provides Higher Manufacturing Yields and Reduces Costs Versus Naturally Harvested Halneuron® -
Read More
New Industry Aims to Create U.S. Manufacturing Jobs While Supporting Colombian Farmers Transitioning to Legal, High-Value Hemp Production
Read MoreCompany plans to distribute Dream Bowl 2026 Meme Coin to shareholders as of a to-be-determined December 2025 date with distribution expected in January 2026
PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner.
Read More"Subsidiaries deliver strong revenue performance as MDCE advances development of innovative AI-driven health and nutrition technologies."
Read More
